Extended Data Fig. 9: Kaplan–Meier curves of EFS by MPR status (PT) in patients with or without pathologic evidence of LN involvement.
From: Association between pathologic response and survival after neoadjuvant therapy in lung cancer

a, Patients with LN involvement who received nivolumab plus chemotherapy and chemotherapy. b, Patients without LN involvement who received nivolumab plus chemotherapy and chemotherapy. CI denotes confidence interval; EFS, event-free survival; LN, lymph node; MPR, major pathologic response; PT, primary tumor.